HPV related surveillance activities in Australia

Comment

Julia Brotherton et al. Vaccine. 2010.

. 2010 Nov 3;28(47):7453-4.

doi: 10.1016/j.vaccine.2010.09.015. Epub 2010 Sep 20.

No abstract available

Comment on

A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.
Bonanni P, Cohet C, Kjaer SK, Latham NB, Lambert PH, Reisinger K, Haupt RM. Bonanni P, et al. Vaccine. 2010 Jul 5;28(30):4719-30. doi: 10.1016/j.vaccine.2010.04.070. Epub 2010 May 6. Vaccine. 2010. PMID: 20451636 Review.

Adverse effects of papillomavirus vaccines: pharmacovigilance data in 2008.
[No authors listed] [No authors listed] Prescrire Int. 2009 Aug;18(102):163. Prescrire Int. 2009. PMID: 19743577
Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance.
Gold MS, McIntyre P. Gold MS, et al. Sex Health. 2010 Sep;7(3):320-4. doi: 10.1071/SH09153. Sex Health. 2010. PMID: 20719221
A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.
Bonanni P, Cohet C, Kjaer SK, Latham NB, Lambert PH, Reisinger K, Haupt RM. Bonanni P, et al. Vaccine. 2010 Jul 5;28(30):4719-30. doi: 10.1016/j.vaccine.2010.04.070. Epub 2010 May 6. Vaccine. 2010. PMID: 20451636 Review.
Post-licensure monitoring of HPV vaccine in the United States.
Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Markowitz LE, et al. Vaccine. 2010 Jul 5;28(30):4731-7. doi: 10.1016/j.vaccine.2010.02.019. Epub 2010 Feb 25. Vaccine. 2010. PMID: 20188681 Review.
Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS. Block SL, et al. Pediatr Infect Dis J. 2010 Feb;29(2):95-101. doi: 10.1097/INF.0b013e3181b77906. Pediatr Infect Dis J. 2010. PMID: 19952863 Clinical Trial.